#San Jose #Costa Rica #SteinCares #Bio-Thera Solutions #Dupilumab

Bio-Thera Solutions and SteinCares' Expanded Partnership

Introduction

In a significant development for the healthcare sector in Latin America, Bio-Thera Solutions, Ltd., a prominent biopharmaceutical company known for its innovative therapies and biosimilars, has partnered with SteinCares, a leader in specialty healthcare distribution in the region. This collaboration aims to commercialize a biosimilar of dupilumab, which is pivotal for treating chronic inflammatory diseases. This initiative represents the fourth venture in their partnership and is expected to make advanced treatments more accessible and affordable for patients across Latin America.

Details of the Partnership

According to the recent announcement made on June 25, 2025, Bio-Thera is tasked with product development and supply, while SteinCares will handle the registration and commercialization aspects of the biosimilar. Dupilumab itself is a top-selling biologic globally, and introducing a biosimilar version is expected to open new doors for patients requiring these treatments.

Mitchell Waserstein, the CEO of SteinCares, emphasized the importance of this partnership in their mission to enhance access to high-quality therapies while ensuring affordability. He stated, "Expanding access to advanced therapies while making healthcare more affordable is central to our mission." Through this collaboration, SteinCares is reinforcing its status as a robust provider of biosimilar therapies, tailoring its offerings to the needs of local patients and healthcare systems.

The Impact on Healthcare

The introduction of a biosimilar for dupilumab addresses a critical healthcare need. Chronic inflammatory diseases can affect individuals of all ages, and the availability of a cost-effective alternative to one of the world’s leading biologics is a potential game changer. This move is not only about expanding treatment options but also about enhancing the overall quality of life for patients suffering from these conditions.

Dr. Shengfeng Li, CEO of Bio-Thera Solutions, echoed this sentiment, expressing confidence in SteinCares as a capable regional partner. By leveraging SteinCares' established commercial network, Bio-Thera aims to expedite the delivery of affordable medications to those who need them most.

SteinCares' Role in Latin America

With operations in over 30 countries across Latin America and the Caribbean, SteinCares bridges the gap between global pharmaceutical innovations and the region’s healthcare systems. The company has a rich history of creating healthcare opportunities that positively impact patient lives, focusing on expanding access to cutting-edge and cost-effective treatments. This partnership with Bio-Thera further solidifies its standing as a go-to partner for international pharmaceutical companies looking to enter the Latin American market.

Conclusion

The collaboration between Bio-Thera Solutions and SteinCares marks a significant step forward in enhancing healthcare access in Latin America. By introducing a biosimilar of dupilumab, the partnership is expected to provide a cost-effective treatment alternative for patients dealing with chronic inflammatory diseases. The emphasis on affordability and availability in this partnership highlights a growing trend in the pharmaceutical industry, where patient welfare takes center stage. As this agreement unfolds, the potential for improved health outcomes in the region looks promising.

For more updates on this collaboration, visit the official websites of Bio-Thera Solutions and SteinCares.